{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:09:33Z","timestamp":1784909373660,"version":"3.55.0"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.28782","type":"journal-article","created":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T21:31:12Z","timestamp":1634506272000},"page":"e2128782","source":"Crossref","is-referenced-by-count":27,"title":["Trends in Insulin Types and Devices Used by Adults With Type 2 Diabetes in the United States, 2016 to 2020"],"prefix":"10.1001","volume":"4","author":[{"given":"Sudipa","family":"Sarkar","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Heyward","sequence":"additional","affiliation":[{"name":"Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Caleb","family":"Alexander","sequence":"additional","affiliation":[{"name":"Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"},{"name":"Division of General Internal Medicine, Johns Hopkins Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita R.","family":"Kalyani","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,10,12]]},"reference":[{"issue":"7","key":"zoi210841r1","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2165\/00044011-200626070-00001","article-title":"A review of 20 years\u2019 experience with the NovoPen family of insulin injection devices.","volume":"26","author":"Rex","year":"2006","journal-title":"Clin Drug Investig"},{"issue":"22","key":"zoi210841r2","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2014.6316","article-title":"Use and out-of-pocket costs of insulin for type 2 diabetes mellitus from 2000 through 2010.","volume":"311","author":"Lipska","year":"2014","journal-title":"JAMA"},{"issue":"13","key":"zoi210841r3","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1001\/jama.2016.0126","article-title":"Expenditures and prices of antihyperglycemic medications in the United States: 2002-2013.","volume":"315","author":"Hua","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"zoi210841r4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11892-020-1286-3","article-title":"Origins of the crisis in insulin affordability and practical advice for clinicians on using human insulin.","volume":"20","author":"Luo","year":"2020","journal-title":"Curr Diab Rep"},{"issue":"1","key":"zoi210841r5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1001\/jama.2017.6939","article-title":"Human insulin for type 2 diabetes: an effective, less-expensive option.","volume":"318","author":"Lipska","year":"2017","journal-title":"JAMA"},{"issue":"12","key":"zoi210841r6","article-title":"Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus.","volume":"12","author":"Fullerton","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"zoi210841r7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1001\/jama.2018.7993","article-title":"Association of initiation of basal insulin analogs vs neutral protamine Hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes.","volume":"320","author":"Lipska","year":"2018","journal-title":"JAMA"},{"key":"zoi210841r8","article-title":"Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus.","volume":"12","author":"Fullerton","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"zoi210841r9","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.2337\/dc14-0031","article-title":"Insulin analogs\u2014are they worth it? yes!","volume":"37","author":"Grunberger","year":"2014","journal-title":"Diabetes Care"},{"issue":"3","key":"zoi210841r10","doi-asserted-by":"publisher","first-page":"590","DOI":"10.2337\/diacare.26.3.590","article-title":"Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.","volume":"26","author":"Vague","year":"2003","journal-title":"Diabetes Care"},{"issue":"4","key":"zoi210841r11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1177\/0897190018815048","article-title":"National trends in diabetes medication use in the United States: 2008 to 2015.","volume":"33","author":"Raval","year":"2020","journal-title":"J Pharm Pract"},{"issue":"7","key":"zoi210841r12","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002638","article-title":"Antihyperglycemic medication use among Medicare beneficiaries with heart failure, diabetes mellitus, and chronic kidney disease.","volume":"9","author":"Patel","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"1","key":"zoi210841r13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1177\/1932296813516956","article-title":"Does device make any difference? a real-world retrospective study of insulin treatment among elderly patients with type 2 diabetes.","volume":"8","author":"Miao","year":"2014","journal-title":"J Diabetes Sci Technol"},{"issue":"3","key":"zoi210841r14","first-page":"278","article-title":"Benchmarking insulin treatment persistence among patients with type 2 diabetes across different US payer segments.","volume":"23","author":"Wei","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"issue":"10","key":"zoi210841r15","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1093\/ajh\/hpx085","article-title":"Current trends of hypertension treatment in the United States.","volume":"30","author":"Shah","year":"2017","journal-title":"Am J Hypertens"},{"issue":"8","key":"zoi210841r16","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1111\/dom.v23.8","article-title":"Ambulatory noninsulin treatment of type 2 diabetes mellitus in the United States, 2015 to 2019.","volume":"23","author":"Heyward","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"zoi210841r17","doi-asserted-by":"publisher","first-page":"985","DOI":"10.2337\/dc13-2097","article-title":"Ambulatory treatment of type 2 diabetes in the US, 1997-2012.","volume":"37","author":"Turner","year":"2014","journal-title":"Diabetes Care"},{"issue":"16","key":"zoi210841r19","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1001\/jama.2019.2990","article-title":"Trends in Medicaid prices, market share, and spending on long-acting insulins, 2006-2018.","volume":"321","author":"Hernandez","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"zoi210841r20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195012","article-title":"Efficacy and safety of biosimilar insulins compared to their reference products: a systematic review.","volume":"13","author":"Tieu","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"zoi210841r21","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1186\/s12913-019-4680-2","article-title":"Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis.","volume":"19","author":"Mansell","year":"2019","journal-title":"BMC Health Serv Res"},{"issue":"7","key":"zoi210841r22","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1001\/jamainternmed.2020.1302","article-title":"Trends in insulin out-of-pocket costs and reimbursement price among US patients with private health insurance, 2006-2017.","volume":"180","author":"Meiri","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"1","key":"zoi210841r23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00125-010-1897-3","article-title":"The insulin dilemma in resource-limited countries: a way forward?","volume":"54","author":"Gill","year":"2011","journal-title":"Diabetologia"},{"key":"zoi210841r24","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108825","article-title":"Correlates of analog vs human basal insulin use among individuals with type 2 diabetes: a cross-sectional study.","volume":"175","author":"Cromer","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"zoi210841r25","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/dom.2018.20.issue-2","article-title":"Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review.","volume":"20","author":"Khunti","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"zoi210841r26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4158\/CS-2019-0472","article-title":"Consensus statement by the American Association Of Clinical Endocrinologists and American College Of Endocrinology on the comprehensive type 2 diabetes management algorithm\u20142020 executive summary.","volume":"26","author":"Garber","year":"2020","journal-title":"Endocr Pract"},{"key":"zoi210841r27","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.2337\/dc21-S009","article-title":"9: Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes\u20142021.","volume":"44","author":"American Diabetes Association","year":"2021","journal-title":"Diabetes Care"},{"issue":"3","key":"zoi210841r28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(15)00521-5","article-title":"Constraints and challenges in access to insulin: a global perspective.","volume":"4","author":"Beran","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"zoi210841r29","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.2337\/dci18-0019","article-title":"Insulin Access and Affordability Working Group: conclusions and recommendations.","volume":"41","author":"Cefalu","year":"2018","journal-title":"Diabetes Care"},{"issue":"36","key":"zoi210841r30","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.15585\/mmwr.mm6936a4","article-title":"Delay or avoidance of medical care because of COVID-19\u2013related concerns\u2014United States, June 2020.","volume":"69","author":"Czeisler","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"zoi210841r33","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.2337\/dc19-2424","article-title":"Use of antihyperglycemic medications in US adults: an analysis of the National Health and Nutrition Examination Survey.","volume":"43","author":"Le","year":"2020","journal-title":"Diabetes Care"},{"issue":"7","key":"zoi210841r34","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1001\/jamainternmed.2020.1302","article-title":"Trends in insulin out-of-pocket costs and reimbursement price among US patients with private health insurance, 2006-2017.","volume":"180","author":"Meiri","year":"2020","journal-title":"JAMA Intern Med"},{"key":"zoi210841r18","volume-title":"Medication Use and Self-Care Practices in People with Diabetes: Diabetes in America","author":"Saydah","year":"2017"},{"key":"zoi210841r31","unstructured":"Centers for Disease Control and Prevention. Diagnosed diabetes. Accessed April 9, 2021. https:\/\/gis.cdc.gov\/grasp\/diabetes\/DiabetesAtlas.html"},{"key":"zoi210841r32","unstructured":"Association of Diabetes Care & Education Specialists. Access and affordability resources. Accessed March 1, 2021. https:\/\/www.diabeteseducator.org\/practice\/practice-tools\/app-resources\/affordability-resources"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2784811\/sarkar_2021_oi_210841_1633035190.31027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T21:31:21Z","timestamp":1634506281000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2784811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.28782","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,12]]}}}